<< Critical biochemical pathways linked to the aging of human muscle identified | Study shows that exposure to radon gas leads to lung cancer >>
Read in | English | 日本語 | 한국어 | Dansk | Bahasa

Comprehensive analysis of monoclonal antibody therapeutics market

Published on September 30, 2009 at 5:47 AM · No Comments

Reportlinker.com announces that a new market research report is available in its catalogue: Reportlinker Adds Monoclonal Antibody Therapeutics 2009-2024

http://www.reportlinker.com/p0151198/Reportlinker-Adds-Monoclonal-Antibody-Therapeutics-2009-2024.html

Monoclonal Antibody Therapeutics 2009-2024 - market growth, novel technologies and expansion into new therapeutic areas - our new report examines the significant commercial opportunities

Monoclonal antibodies achieved total sales of nearly $32bn in 2008 and have grown rapidly to command over 30% of the global biologic drug market. We expect significant opportunities for further commercial growth from 2009 to 2024, as shown in our new report, Monoclonal Antibody Therapeutics 2009-2024. New technologies will be an important growth driver. Intensive R&D activity is producing an exciting antibody pipeline, filled with novel monoclonal antibodies, antibody fragments and antibody-drug conjugates. Furthermore, monoclonal antibodies already on the market have scope for additional development. In particular, the author foresees the application of monoclonal antibodies in new therapeutic areas, outside the currently-established fields.

At the same time, challenges and changes lie ahead. Increased competition for antibody targets and patient populations, pricing pressures from governments and other healthcare payers, patent expiry for high-revenue monoclonal antibodies and the spectre of biosimilar monoclonal antibodies will come to the fore during the period 2009 to 2024.

What will be the characteristics of drugs that will succeed Avastin and Remicade, becoming the blockbusters of the future? What are the potential applications and prospects for antibody fragments? Which pipeline drugs are the ones to watch? Our completely updated report - packed with 140 tables and figures – will show you the outlook for this dynamic sector of the pharmaceutical market.

Comprehensive analysis of the monoclonal antibody therapeutics market

Monoclonal Antibody Therapeutics 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are also three detailed interviews with authorities on the sector in this 200+ page report. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.

Why you should buy this report

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading